Kalocyte, Inc., HEMARINA, Hemoglobin Oxygen Therapeutics LLC Farms are Dominating the Global Artificial Blood Substitutes Market in 2020

Global Artificial Blood Substitutes Market is expected to grow with the CAGR of 25.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-artificial-blood-substitutes-market

Global artificial blood substitutes market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global artificial blood substitutes market are introducing strong range of products provider along with adopting strategic initiative such as acquisition, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In November 2020, Hemarina and The Brest CHRU conducted OxyOp2 study in which they crossed 100 participants. This study has evaluated the effectiveness of the universal oxygen carrier HEMO2 in the renal transplant.

KaloCyte, Inc. is the dominating player in global artificial blood substitutes market. The other key players existing in the market are HEMARINA, Hemoglobin Oxygen Therapeutics LLC, LLC “Visusmed”, European Medicines Agency, OPK Biotech LLC, NuvOx Pharma, Prolong Pharmaceuticals, LLC, Boston Therapeutics, Inc., Aurum Biosciences, OXYVITA Inc. and NanoBlood LLC.

Artificial Blood Substitutes MarketKaloCyte, Inc.

KaloCyte, Inc., founded in 2016 and headquarter is in Maryland, U.S.. The company is focused developing ErythroMer, a dried, bio-inspired artificial red blood cell to use when the stored RBCs are undesirable, unavailable or short in storage. The company has product categories Erythromer in which is also the market focused category.

For instance,

  • In June 2020, KaloCyte, Inc. received a USD 300k funding from University System of Maryland (USM) Momentum Fund for developing ErythroMer, a synthetic, bio-inspired red blood substitute. This funding has helped the company in developing the ErythroMer at much faster pace.

The company has wide presence across North America.


HEMARINA, founded in the year 2007, headquarter in Morlaix, France. Their main focus of the company is on specialization of health care products by using proprietary technological platform (M101) to meet all the medical needs by innovative approach. The company offeres product category including Hemo2life, Hemoxycarrier, Hemhealing, Hemoxcell, Hemdental-Care, Hemboost in which Hemoxycarrier is the market focused segment.

For instance,

  • In November 2020, Hemarina published a scientific report for anti-inflammatory and antibacterial property of M 101, an oxygen transporter for the treatment of periodontitis. This study has validated the quality of M 101 molecolue, which is derived from haemoglobin of the marine lugworm.

The company has presence across Europe.

Hemoglobin Oxygen Therapeutics LLC

Hemoglobin Oxygen Therapeutics LLC, headquarter in Pennsylvania, U.S. The main focus of the company is to developing human and veterinary hemoglobin-based oxygen carriers (HBOCs) to increase the oxygen-carrying capacity of blood. The company has product category in segments including Oxygen Carrying Solution, Quality & Manufacturing in which Oxygen Carrying Solution is the market focused category.

For instance,

  • In April 2019, Hemoglobin Oxygen Therapeutics LLC announced the publication of its preclinical data which demonstrated that the Hempure could replace packed red blood cells (RBCs) in normothermic kidney perfusion (NMP). This announcement helped the company in gaining significant interest in the organ transplantation field.

The company has presence across North America.